Last reviewed · How we verify

metoprolol, amiodarone

Kuopio University Hospital · FDA-approved active Small molecule

Metoprolol is a beta-1 selective adrenergic antagonist that reduces heart rate and blood pressure, while amiodarone is a class III antiarrhythmic that blocks potassium channels and prolongs the action potential duration to prevent arrhythmias.

Metoprolol is a beta-1 selective adrenergic antagonist that reduces heart rate and blood pressure, while amiodarone is a class III antiarrhythmic that blocks potassium channels and prolongs the action potential duration to prevent arrhythmias. Used for Hypertension, Angina pectoris, Myocardial infarction.

At a glance

Generic namemetoprolol, amiodarone
SponsorKuopio University Hospital
Drug classBeta-1 selective adrenergic antagonist; Class III antiarrhythmic
TargetBeta-1 adrenergic receptor; Potassium channels (hERG and others)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Metoprolol competitively blocks beta-1 adrenergic receptors on the heart, decreasing contractility and heart rate. Amiodarone is a potent antiarrhythmic with multiple mechanisms including potassium channel blockade (class III effect), sodium channel inhibition (class I), beta-blockade (class II), and calcium channel blockade (class IV), making it effective for both atrial and ventricular arrhythmias. Together, they provide complementary cardiac effects for rate and rhythm control.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: